Kritoma

Discovery

Explore Topics Papers

Docs Terms Privacy

Search Kritoma

Recent searches

Searches you run from this bar will appear here.

GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Knowledge Timeline Gaps (1)Evidence (359)Community (0)

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

251 papers

SearchSort evidence

All359 Core251 Supporting111 Background0

Active filtersClassification:Core

Showing 1-12 of total 251 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026CrossrefDirectly related1 citations

Incretin‐Based Therapies: A Testable Hypothesis Linking Incretin Signaling, Mitochondrial Redox, and <scp>OXPHOS</scp> Efficiency

Bryn Falahee; Caroline M. Apovian; Nawfal Istfan

Sep 24, 2026Obesity

2026CrossrefDirectly related0 citations

Cardiovascular protection beyond glucose lowering: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism in contemporary cardiology

Mingzhe Li

Sep 16, 2026Frontiers in Cardiovascular Medicine

2026CrossrefDirectly related0 citations

Obesity-driven Cardiovascular Risk: Role of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists

Amandeep Kaur; Okesh Saini; Mohd Haneef; sourabh Kosey

Sep 14, 2026Glucolipid Metabolic Disorders

2026CrossrefDirectly related0 citations

Incretin‐Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor‐Network Pharmacology and Phenotype‐Based Clinical Positioning

Ferenc Sztanek; Hajnalka Lőrincz; Mariann Harangi; Attila Csaba Nagy

Sep 1, 2026Diabetes, Obesity and Metabolism

2026CrossrefDirectly related1 citations

Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk

Jan Kafol; Borut Jug; Zlatko Fras

Jul 20, 2026Cells

2026CrossrefDirectly related0 citations

OPTIONS AND LIMITATIONS OF OBESITY TREATMENT WITH GLP-1 RECEPTOR AGONISTS

Katarína Babíková

Jun 1, 2026Ateroskleróza

2026CrossrefDirectly related0 citations

Do Glucagon-Like Peptide-1 Receptor Agonists Sabotage Fat Grafts?: A Scoping Review of Glucagon-Like Peptide-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer

Xavier Chalhoub; Zhi Yang Ng

Jun 1, 2026Aesthetic Surgery Journal

2026CrossrefDirectly related0 citations

GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists in Children and Adolescents with Obesity: Clinical Outcomes and the Impact of Nutritional and Behavioral Co-Interventions—A Systematic Review

Dominika Myśliwczyk; Krzysztof Ksawery Gofron; Andrzej Wasilewski; Małgorzata Myśliwiec; Eliza Wasilewska

May 22, 2026Nutrients

2026CrossrefDirectly related0 citations

How do Dual GLP-1/GIP Receptor Agonists Differ from GLP-1 Agonists for Diabetes Management: A Systematic Review

Prisha Bhat

Apr 16, 2026Undergraduate Research in Natural and Clinical Science and Technology Journal

2026CrossrefDirectly related2 citations

GLP-1 RAs for Treating Metabolic Dysfunction-Associated Steatosis Liver Disease: From GLP-1 Discovery to FDA Approval: A Comprehensive Narrative Review

Olfa Khalifa; Abdelilah Arredouani

Mar 1, 2026Pharmaceuticals

2026CrossrefDirectly related0 citations

Eyes on GLP-1 receptor agonists

Bence Tasnadi

Jan 14, 2026Journal of the Foundations of Ophthalmology

2026PubMedDirectly related

Impact of Glucagon-Like Peptide-1 Receptor Agonists on Mental Health: A Systematic Review of Psychiatric Safety and Antidepressant Potential.

Quadir A; Devi R; Jad Allah B; Haider A; Shaikh SS; Botsa KN

Jan 1, 2026Cureus

Page 1 of 21Showing 1-12 of total 251 results.

12...21

GLP-1 receptor agonists for obesity treatment — Research Evidence and Topic... | Kritoma